Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Acknowledgments

Financial support for this research project was provided by the Edna McConnell Clark Foundation of New York, through a grant to Harvard University. The authors would like to thank all the participants in the study, including individuals at the World Health Organization, the World Bank, UNICEF, UNIPAC, the Egyptian Ministry of Health, and various universities, government agencies, and research institutions around the world. These individuals graciously provided time and materials during the research phase and then reviewed drafts of this study and offered useful comments and input. The many contributions to this report from Dr Kenneth Mott of WHO are especially recognized by the authors. The authors also thank the Action Programme on Essential Drugs, particularly Mrs P. Brudon, for the excellent assistance in publication of this report. In addition, the authors appreciate the cooperation of four private firms involved in praziquantel production: Bayer, E. Merck, Shin Poong Pharmaceutical Co., and the Egyptian International Pharmaceutical Industries Co. (EIPICO). Special thanks are due to Dr Joseph Cook and Mr Jeffrey Mecaskey of the Edna McConnell Clark Foundation for their consistent support of the study.

A number of researchers in an international team contributed to the writing of this report. The introduction was written by the study’s principal investigator, Michael R. Reich, and Ramesh Govindaraj. Chapter 2, on the discovery and development of praziquantel, was written by Michael R. Reich, Agnes Brinkmann, and Ramesh Govindaraj, using published materials and interviews. Chapter 3, on the discovery and development of an alternative production process for praziquantel in the Republic of Korea, was authored by Bong-min Yang. Chapter 4, on the formulation of praziquantel in Egypt, was co-authored by Michael R. Reich and Sameh El Saharty, based on interviews and data collected in Egypt. Chapter 5, on the international supply of praziquantel, was written by Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh. Chapter 6, on the global demand for praziquantel, was written by Michael R. Reich and Ramesh Govindaraj, with assistance from John Norris on gathering national data of praziquantel availability and from Christopher Mast and Agnes Brinkmann on praziquantel distribution in Mali. Chapter 7, on global prices and production costs of praziquantel, was written by Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014